III 期临床启动,意味着新药研发已经开始向上市申请发起冲刺。Insight 数据库显示,2025 年 6 月(数据范围 6.1-6.26),多款国产新药(包括改良新)启动关键 III 期临床,其中多款为首次启动。恒瑞医药启动 Myosin 抑制剂、口服 ER 降解剂、GLP1R/GIPR 双激动剂分别用于梗阻性肥厚型心肌病、乳腺癌、2 型糖尿病的关键 III 期;百济神州首次启动替雷利珠单抗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.